Table 1 Clinical characteristic of subjects with CVD at inclusion in the Registry according to statin prescribed, and lipid values at diagnosis of dyslipidemia in the Lipid Clinic without lipid-lowering treatment and after lipid-lowering treatment recorded at inclusion in the Registry
Variables | Atorvastatin (n = 243) | Rosuvastatin (n = 164) | P |
|---|---|---|---|
Gender (Male), % (n) | 78.2 [190] | 68.9 [113] | 0.046 |
Age at inclusion, years | 60.9 (11.1) | 60.6 (9.9) | 0.743 |
Body mass index, (Kg/m2) | 28.9 (4.1) | 28.6 (4.3) | 0.595 |
ASCVD type (CHD/Stroke/PAD), % | 77.3/14.5/7.0 | 79.3/12.2/5.5 | 0.460 |
Age first ASCVD event | 51.7 (11.4) | 51.1 (10.5) | 0.561 |
Tobacco consumption, % (n) | 18.9 [45] | 15.5 [25] | 0.461 |
Hypertension, % (n) | 48.6 [118] | 56.1 [92] | 0.164 |
Diabetes, % (n) | 30.9 [75] | 31.7 [52] | 0.943 |
Glucose, mg/dL | 113.6 (33.5) | 108.4 (32.4) | 0.130 |
Age statin onset | 48.4 (12.3) | 49.4 (11.2) | 0.477 |
Total cholesterol, mg/dl | |||
Pre-treatment | 296.8 (102.6) | 322.1 (111.1) | 0.020 |
Post-treatment | 172.9 (55.6) | 182.6 (49.8) | 0.065 |
HDL cholesterol, mg/dl | |||
Pre-treatment | 45.2 (14.3) | 46.6 (12.8) | 0.285 |
Post-treatment | 47.1 (13.8) | 49.6 (11.6) | 0.048 |
Non-HDL cholesterol, mg/dl | |||
Pre-treatment | 251.6 (100.8) | 275.5 (109.9) | 0.027 |
Post-treatment | 110.6 (39.9) | 119.0 (49.5) | 0.072 |
Triglycerides, mg/dl | |||
Pre-treatment | 241.5 (291.3) | 209.2 (229.4) | 0.213 |
Post-treatment | 161.5 (175.2) | 160.2 (153.8) | 0.938 |
Statin daily dose, mg/day | 50.8 (24.7) | 21.4 (9.6) | – |
Ezetimibe use, % (n) | 57.9 [140] | 69.5 [114] | 0.023 |